{"id":"https://openalex.org/W1995745448","doi":"https://doi.org/10.3851/imp1759","title":"Baseline CD4 + T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients","display_name":"Baseline CD4 + T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients","publication_year":2010,"publication_date":"2010-04-01","ids":{"openalex":"https://openalex.org/W1995745448","doi":"https://doi.org/10.3851/imp1759","mag":"1995745448","pmid":"https://pubmed.ncbi.nlm.nih.gov/21555822"},"language":"en","primary_location":{"id":"doi:10.3851/imp1759","doi":"https://doi.org/10.3851/imp1759","is_oa":false,"landing_page_url":"https://doi.org/10.3851/imp1759","pdf_url":null,"source":{"id":"https://openalex.org/S137629795","display_name":"Antiviral Therapy","issn_l":"1359-6535","issn":["1359-6535","2040-2058"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antiviral Therapy","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5110224117","display_name":"Jonathan Schapiro","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jonathan M Schapiro","raw_affiliation_strings":["National Hemophilia Center, Tel Hashomer, Israel"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Hemophilia Center, Tel Hashomer, Israel","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103011545","display_name":"Charles A. Boucher","orcid":"https://orcid.org/0000-0003-0892-5473","observed_orcids":["https://orcid.org/0000-0003-0892-5473"]},"institutions":[{"id":"https://openalex.org/I2801952686","display_name":"Erasmus MC","ror":"https://ror.org/018906e22","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2801952686"]},{"id":"https://openalex.org/I3018483916","display_name":"University Medical Center Utrecht","ror":"https://ror.org/0575yy874","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I3018483916"]},{"id":"https://openalex.org/I913958620","display_name":"Erasmus University Rotterdam","ror":"https://ror.org/057w15z03","country_code":"NL","type":"education","lineage":["https://openalex.org/I913958620"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Charles AB Boucher","raw_affiliation_strings":["Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands","Department of Virology, Erasmus Medical Centre, Erasmus University, Rotterdam, the Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands","institution_ids":["https://openalex.org/I3018483916"]},{"raw_affiliation_string":"Department of Virology, Erasmus Medical Centre, Erasmus University, Rotterdam, the Netherlands","institution_ids":["https://openalex.org/I2801952686","https://openalex.org/I913958620"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058715015","display_name":"Daniel R. Kuritzkes","orcid":"https://orcid.org/0000-0001-6196-5883","observed_orcids":["https://orcid.org/0000-0001-6196-5883"]},"institutions":[{"id":"https://openalex.org/I1283280774","display_name":"Brigham and Women's Hospital","ror":"https://ror.org/04b6nzv94","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I121934306","https://openalex.org/I1283280774","https://openalex.org/I48633490"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel R Kuritzkes","raw_affiliation_strings":["Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA","institution_ids":["https://openalex.org/I1283280774","https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084575089","display_name":"David A. M. C. van de Vijver","orcid":"https://orcid.org/0000-0001-5877-8526","observed_orcids":["https://orcid.org/0000-0001-5877-8526"]},"institutions":[{"id":"https://openalex.org/I2801952686","display_name":"Erasmus MC","ror":"https://ror.org/018906e22","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2801952686"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"David A van de Vijver","raw_affiliation_strings":["Erasmus Medical Centre, University Medical Centre Rotterdam, Rotterdam, the Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Erasmus Medical Centre, University Medical Centre Rotterdam, Rotterdam, the Netherlands","institution_ids":["https://openalex.org/I2801952686"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029931096","display_name":"Josep Maria Llibre","orcid":"https://orcid.org/0000-0002-7158-6753","observed_orcids":["https://orcid.org/0000-0002-7158-6753"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Josep M Llibre","raw_affiliation_strings":["Lluita contra la SIDA Foundation, Hospital Germans Trias i Pujol, Badalona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lluita contra la SIDA Foundation, Hospital Germans Trias i Pujol, Badalona, Spain","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111807565","display_name":"Marilyn Lewis","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189718659","display_name":"Pfizer (United Kingdom)","ror":"https://ror.org/04x4v8p40","country_code":"GB","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I189718659"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Marilyn Lewis","raw_affiliation_strings":["Pfizer Global Research & Development, Sandwich, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Global Research & Development, Sandwich, UK","institution_ids":["https://openalex.org/I189718659"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Paul Simpson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189718659","display_name":"Pfizer (United Kingdom)","ror":"https://ror.org/04x4v8p40","country_code":"GB","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I189718659"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Paul Simpson","raw_affiliation_strings":["Pfizer Global Research & Development, Sandwich, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Global Research & Development, Sandwich, UK","institution_ids":["https://openalex.org/I189718659"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020376658","display_name":"Christophe Delogne","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189718659","display_name":"Pfizer (United Kingdom)","ror":"https://ror.org/04x4v8p40","country_code":"GB","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I189718659"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Christophe Delogne","raw_affiliation_strings":["Pfizer Global Research & Development, Sandwich, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Global Research & Development, Sandwich, UK","institution_ids":["https://openalex.org/I189718659"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035996923","display_name":"Lynn McFadyen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189718659","display_name":"Pfizer (United Kingdom)","ror":"https://ror.org/04x4v8p40","country_code":"GB","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I189718659"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Lynn McFadyen","raw_affiliation_strings":["Pfizer Global Research & Development, Sandwich, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Global Research & Development, Sandwich, UK","institution_ids":["https://openalex.org/I189718659"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113660761","display_name":"Douglass S. Chapman","orcid":"https://orcid.org/0009-0005-4067-1954","observed_orcids":["https://orcid.org/0009-0005-4067-1954"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Douglass Chapman","raw_affiliation_strings":["Pfizer Inc, New York, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc, New York, NY, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069464538","display_name":"Manos Perros","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189718659","display_name":"Pfizer (United Kingdom)","ror":"https://ror.org/04x4v8p40","country_code":"GB","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I189718659"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Manos Perros","raw_affiliation_strings":["Pfizer Global Research & Development, Sandwich, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Global Research & Development, Sandwich, UK","institution_ids":["https://openalex.org/I189718659"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089961811","display_name":"Hern\u00e1n Valdez","orcid":"https://orcid.org/0000-0001-8058-1922","observed_orcids":["https://orcid.org/0000-0001-8058-1922"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Hernan Valdez","raw_affiliation_strings":["Pfizer Inc, New York, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc, New York, NY, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062304028","display_name":"Elna van der Ryst","orcid":"https://orcid.org/0000-0002-9193-1825","observed_orcids":["https://orcid.org/0000-0002-9193-1825"]},"institutions":[{"id":"https://openalex.org/I189718659","display_name":"Pfizer (United Kingdom)","ror":"https://ror.org/04x4v8p40","country_code":"GB","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I189718659"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Elna van der Ryst","raw_affiliation_strings":["Pfizer Global Research & Development, Sandwich, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Global Research & Development, Sandwich, UK","institution_ids":["https://openalex.org/I189718659"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5084731018","display_name":"Mike Westby","orcid":"https://orcid.org/0009-0000-2612-6689","observed_orcids":["https://orcid.org/0009-0000-2612-6689"]},"institutions":[{"id":"https://openalex.org/I189718659","display_name":"Pfizer (United Kingdom)","ror":"https://ror.org/04x4v8p40","country_code":"GB","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I189718659"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Mike Westby","raw_affiliation_strings":["Pfizer Global Research & Development, Sandwich, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Global Research & Development, Sandwich, UK","institution_ids":["https://openalex.org/I189718659"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":7,"corresponding_author_ids":["https://openalex.org/A5089961811"],"corresponding_institution_ids":["https://openalex.org/I180857899"],"apc_list":{"value":2800,"currency":"USD","value_usd":2800},"apc_paid":null,"fwci":1.6681,"has_fulltext":false,"cited_by_count":21,"citation_normalized_percentile":{"value":0.82646538,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"16","issue":"3","first_page":"395","last_page":"404"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10112","display_name":"HIV Research and Treatment","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10082","display_name":"HIV/AIDS Research and Interventions","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/maraviroc","display_name":"maraviroc","score":1.0},{"id":"https://openalex.org/keywords/hiv-1","display_name":"HIV-1","score":0.7990000247955322},{"id":"https://openalex.org/keywords/treatment-experienced-patients","display_name":"treatment-experienced patients","score":0.8610000014305115},{"id":"https://openalex.org/keywords/virological-response","display_name":"virological response","score":0.7429999709129333},{"id":"https://openalex.org/keywords/genotypic-resistance-testing","display_name":"genotypic resistance testing","score":0.8090000152587891},{"id":"https://openalex.org/keywords/phenotypic-resistance-testing","display_name":"phenotypic resistance testing","score":0.9940000176429749},{"id":"https://openalex.org/keywords/ccr5-antagonist","display_name":"CCR5 antagonist","score":0.6309999823570251},{"id":"https://openalex.org/keywords/predictors-of-treatment-response","display_name":"predictors of treatment response","score":0.6610000133514404}],"concepts":[{"id":"https://openalex.org/C2778899366","wikidata":"https://www.wikidata.org/wiki/Q421369","display_name":"Maraviroc","level":3,"score":0.9826661348342896},{"id":"https://openalex.org/C37044404","wikidata":"https://www.wikidata.org/wiki/Q5009692","display_name":"CCR5 receptor antagonist","level":5,"score":0.7747578620910645},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6437206864356995},{"id":"https://openalex.org/C142462285","wikidata":"https://www.wikidata.org/wiki/Q2528140","display_name":"Viral load","level":3,"score":0.6050059795379639},{"id":"https://openalex.org/C151956035","wikidata":"https://www.wikidata.org/wiki/Q1132755","display_name":"Logistic regression","level":2,"score":0.6046615839004517},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5979573130607605},{"id":"https://openalex.org/C35693153","wikidata":"https://www.wikidata.org/wiki/Q239762","display_name":"Tropism","level":3,"score":0.5168295502662659},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.4345189332962036},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.2894607186317444},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.1009182333946228},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.06787535548210144},{"id":"https://openalex.org/C13373296","wikidata":"https://www.wikidata.org/wiki/Q421866","display_name":"Chemokine","level":3,"score":0.0},{"id":"https://openalex.org/C12823836","wikidata":"https://www.wikidata.org/wiki/Q24720618","display_name":"Chemokine receptor","level":4,"score":0.0}],"mesh":[{"descriptor_ui":"D000077592","descriptor_name":"Maraviroc","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077592","descriptor_name":"Maraviroc","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077592","descriptor_name":"Maraviroc","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003510","descriptor_name":"Cyclohexanes","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003510","descriptor_name":"Cyclohexanes","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003510","descriptor_name":"Cyclohexanes","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003510","descriptor_name":"Cyclohexanes","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D003510","descriptor_name":"Cyclohexanes","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D003510","descriptor_name":"Cyclohexanes","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D003510","descriptor_name":"Cyclohexanes","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D003510","descriptor_name":"Cyclohexanes","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D003510","descriptor_name":"Cyclohexanes","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D005838","descriptor_name":"Genotype","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005838","descriptor_name":"Genotype","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005838","descriptor_name":"Genotype","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008826","descriptor_name":"Microbial Sensitivity Tests","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008826","descriptor_name":"Microbial Sensitivity Tests","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008826","descriptor_name":"Microbial Sensitivity Tests","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010641","descriptor_name":"Phenotype","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010641","descriptor_name":"Phenotype","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010641","descriptor_name":"Phenotype","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011237","descriptor_name":"Predictive Value of Tests","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011237","descriptor_name":"Predictive Value of Tests","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011237","descriptor_name":"Predictive Value of Tests","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012367","descriptor_name":"RNA, Viral","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D012367","descriptor_name":"RNA, Viral","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D012367","descriptor_name":"RNA, Viral","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D013601","descriptor_name":"T-Lymphocytes","qualifier_ui":"Q000821","qualifier_name":"virology","is_major_topic":false},{"descriptor_ui":"D013601","descriptor_name":"T-Lymphocytes","qualifier_ui":"Q000821","qualifier_name":"virology","is_major_topic":false},{"descriptor_ui":"D013601","descriptor_name":"T-Lymphocytes","qualifier_ui":"Q000821","qualifier_name":"virology","is_major_topic":false},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000821","qualifier_name":"virology","is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000821","qualifier_name":"virology","is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000821","qualifier_name":"virology","is_major_topic":false},{"descriptor_ui":"D016015","descriptor_name":"Logistic Models","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016015","descriptor_name":"Logistic Models","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016015","descriptor_name":"Logistic Models","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017326","descriptor_name":"Clinical Trials, Phase III as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017326","descriptor_name":"Clinical Trials, Phase III as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017326","descriptor_name":"Clinical Trials, Phase III as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018791","descriptor_name":"CD4 Lymphocyte Count","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018791","descriptor_name":"CD4 Lymphocyte Count","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018791","descriptor_name":"CD4 Lymphocyte Count","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D019562","descriptor_name":"Viral Load","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019562","descriptor_name":"Viral Load","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019562","descriptor_name":"Viral Load","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D023581","descriptor_name":"HIV Fusion Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D023581","descriptor_name":"HIV Fusion Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D023581","descriptor_name":"HIV Fusion Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D023581","descriptor_name":"HIV Fusion Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D023581","descriptor_name":"HIV Fusion Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D023581","descriptor_name":"HIV Fusion Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D023581","descriptor_name":"HIV Fusion Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D023581","descriptor_name":"HIV Fusion Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D023581","descriptor_name":"HIV Fusion Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D024882","descriptor_name":"Drug Resistance, Viral","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D024882","descriptor_name":"Drug Resistance, Viral","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D024882","descriptor_name":"Drug Resistance, Viral","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D024882","descriptor_name":"Drug Resistance, Viral","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D024882","descriptor_name":"Drug Resistance, Viral","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D024882","descriptor_name":"Drug Resistance, Viral","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D065100","descriptor_name":"CCR5 Receptor Antagonists","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D065100","descriptor_name":"CCR5 Receptor Antagonists","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D065100","descriptor_name":"CCR5 Receptor Antagonists","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.3851/imp1759","doi":"https://doi.org/10.3851/imp1759","is_oa":false,"landing_page_url":"https://doi.org/10.3851/imp1759","pdf_url":null,"source":{"id":"https://openalex.org/S137629795","display_name":"Antiviral Therapy","issn_l":"1359-6535","issn":["1359-6535","2040-2058"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antiviral Therapy","raw_type":"journal-article"},{"id":"pmid:21555822","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21555822","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antiviral therapy","raw_type":"Journal Article"},{"id":"pmh:eur:oai:pure.eur.nl:publications/ae1f6ccc-3e11-4383-a854-3209e6e40d8a","doi":null,"is_oa":false,"landing_page_url":"https://pure.eur.nl/en/publications/ae1f6ccc-3e11-4383-a854-3209e6e40d8a","pdf_url":null,"source":{"id":"https://openalex.org/S4306401266","display_name":"EUR Research Repository (Erasmus University Rotterdam)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I913958620","host_organization_name":"Erasmus University Rotterdam","host_organization_lineage":["https://openalex.org/I913958620"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Antiviral Therapy, 16(3), 395 - 404. International Medical Press Ltd","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9922999739646912,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"score":0.8100000023841858,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":26,"referenced_works":["https://openalex.org/W1933602578","https://openalex.org/W1973948212","https://openalex.org/W1983837630","https://openalex.org/W1985722970","https://openalex.org/W1993642436","https://openalex.org/W1999048558","https://openalex.org/W2015750495","https://openalex.org/W2016264635","https://openalex.org/W2016572755","https://openalex.org/W2019952737","https://openalex.org/W2024353108","https://openalex.org/W2030569433","https://openalex.org/W2040557088","https://openalex.org/W2043590076","https://openalex.org/W2066033112","https://openalex.org/W2089568674","https://openalex.org/W2110215558","https://openalex.org/W2139772076","https://openalex.org/W2140708560","https://openalex.org/W2146010749","https://openalex.org/W2153650518","https://openalex.org/W2183940924","https://openalex.org/W2312642584","https://openalex.org/W2331269392","https://openalex.org/W2346099372","https://openalex.org/W4236479494"],"related_works":["https://openalex.org/W1711663650","https://openalex.org/W2032712974","https://openalex.org/W2089568674","https://openalex.org/W2408391488","https://openalex.org/W2995503803","https://openalex.org/W2022425630","https://openalex.org/W2127472689","https://openalex.org/W2037255412","https://openalex.org/W3192112847","https://openalex.org/W2085437852"],"abstract_inverted_index":{"BACKGROUND:":[0],"Maraviroc-containing":[1],"regimens":[2],"are":[3],"known":[4],"to":[5,16,23,31,41,178],"achieve":[6],"virological":[7,106,141,161,175,233],"suppression":[8],"in":[9,26,220],"many":[10],"treatment-experienced":[11],"patients.":[12],"This":[13],"study":[14],"aimed":[15],"evaluate":[17],"a":[18,95,169,174,195],"more":[19],"rigorous":[20],"methodological":[21],"approach":[22],"resistance-response":[24],"analysis":[25],"large":[27],"clinical":[28],"studies":[29],"and":[30,47,123,143,151,225],"better":[32,144],"establish":[33],"which":[34],"subpopulations":[35],"of":[36,89,99,105,140,160,165,192,206,232],"patients":[37,167,193],"were":[38,65,125,137,156,229],"most":[39],"likely":[40],"benefit":[42],"from":[43,52],"maraviroc":[44,113,166,202],"by":[45,67,127],"refining":[46],"extending":[48],"previous":[49],"subgroup":[50],"analyses":[51],"the":[53,157,181,204,221],"MOTIVATE":[54,222],"studies.":[55,223],"METHODS:":[56],"Individual":[57],"weighted":[58,109,135,170,227],"optimized":[59],"background":[60],"therapy":[61],"(OBT)":[62],"susceptibility":[63],"scores":[64,228],"calculated":[66],"combining":[68],"genotypic":[69],"or":[70,110,133],"phenotypic":[71,134,226],"resistance":[72],"testing":[73],"with":[74,94,168,194,203],"prior":[75],"drug":[76],"use":[77],"information.":[78],"Virological":[79],"response":[80,142,162],"(HIV-1":[81],"RNA<50":[82,215],"copies/ml":[83,216],"at":[84,207,217],"week":[85,218],"48)":[86],"using":[87],"each":[88],"these":[90],"methods":[91,136],"was":[92,186],"compared":[93],"commonly":[96],"used":[97],"method":[98],"counting":[100,146],"active":[101,147,211],"drugs.":[102,148],"Baseline":[103],"predictors":[104,159],"response,":[107,176],"including":[108],"unweighted":[111],"scoring,":[112],"use,":[114],"baseline":[115,152,182],"CD4(+)":[116,153,183,196],"T-cell":[117,154,184,197],"count,":[118],"HIV-1":[119,214],"plasma":[120],"viral":[121],"load":[122],"tropism,":[124],"assessed":[126],"logistic":[128],"regression":[129],"modelling.":[130],"RESULTS:":[131],"Genotypic":[132,224],"similarly":[138,230],"predictive":[139,231],"than":[145],"Weighted":[149],"scoring":[150],"count":[155,185,198],"strongest":[158],"(P<0.0001):":[163],"\u224870%":[164],"score":[171],"\u22652":[172],"had":[173],"rising":[177],"\u224880%":[179],"when":[180],"\u226550":[187,199],"cells/mm(3).":[188],"CONCLUSIONS:":[189],"Approximately":[190],"80%":[191],"cells/mm(3)":[200],"receiving":[201],"equivalent":[205],"least":[208],"two":[209],"fully":[210],"agents":[212],"achieved":[213],"48":[219],"response.":[234]},"counts_by_year":[{"year":2021,"cited_by_count":2},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2015,"cited_by_count":7},{"year":2013,"cited_by_count":4},{"year":2012,"cited_by_count":3}],"updated_date":"2026-10-25T09:29:13.331239","created_date":"2016-06-24T00:00:00"}